LYVE-1ÓëѪ¹ÜÄÚƤÉú³¤Òò×Ó-CÔÚºíÁÛ״ϸ°û°©Öеıí´ï
ºÍÒâÒå
ÕÅ´ºÃ÷;Íõ±óÈ«;»Ê¸¦»Ô;ÎÂÊ÷ÐÅ;Õź£Àû
¡¾ÆÚ¿¯Ãû³Æ¡¿¡¶Ö×ÁöÑо¿ÓëÁÙ´²¡· ¡¾Äê(¾í),ÆÚ¡¿2009(021)002
¡¾ÕªÒª¡¿Ä¿µÄ ͨ¹ý²â¶¨ºíÁÛ״ϸ°û°©×éÖ¯ÄÚLYVE-1ºÍѪ¹ÜÄÚƤÉú³¤Òò×Ó-C(VEGF-C)µÄ±í´ïÇé¿ö,ΪºíÁÛ״ϸ°û°©×ªÒƺÍÔ¤ºóµÄÅж¨ÒÔ¼°ÖÎÁÆÌṩһ¶¨µÄÀíÂÛÒÀ¾Ý.·½·¨ ͨ¹ýÃâÒß²¡Àíѧ·½·¨¼ì²âLYVE-1µÄ±í´ï²¢¼ÆÊýºíÁÛ״ϸ°û°©×éÖ¯ÖÐÁܰ͹ÜÃܶÈ(LVD),RT-PCR·¨¼ì²âºíÁÛ״ϸ°û°©ÖÐVEGF-CµÄ±í´ï,ʹÓÃͳ¼Æѧ·½·¨¶ÔLVDºÍVEGF-C±í´ï½øÐзÖÎö.½á¹û ºí°©×éÖ¯ÄÚ´æÔÚLYVE-1(+)µÄ¹ÜÇ»Ñù½á¹¹,LYVE-1ÔÚºí°©×éÖ¯ºÍ°©ÅÔÕý³£×éÖ¯Ö®¼ä±í´ï²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.05),ºí°©×éÖ¯ÖÐVEGF-C mRNAµÄƽ¾ùˮƽÓëÕý³£×éÖ¯Ö®¼ä²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.05),Áö×éÖ¯±ÈÕý³£×éÖ¯¸ß4¡«5±¶,¶øÇÒºí°©×éÖ¯ÄÚVEGF-C±í´ïÓëLVDÖ®¼ä´æÔÚÏà¹ØÐÔ.½áÂÛ ºíÁÛ״ϸ°û°©Áö×éÖ¯ÖдæÔÚÁܰ͹Ü;VEGF-C mRNAÔÚºíÁÛ״ϸ°û°©×éÖ¯Öеıí´ïÒª±ÈÕý³£¶ÔÕÕ×éÖ¯¸ß,ÇÒVEGF-C mRNAµÄ¸ß±í´ï¿ÉÄÜ»áͨ¹ý´Ù½øÁöÄÚÁܰ͹ܵÄÔöÉúÀ´´Ù½øºí°©µÄÁܰͽáתÒÆ.%Objective To elucidate the relationship between LYVE-1 and VEGF-C and their expression in laryngeal squamous cell carcinoma(LSCC),and provide theoretic evidence for the judgement of metastasis and prognosis of LSCC,also for the treatment.Methods An immunohistocbemical analysis was performed to 50 specimens of LSCC with lymphatic endothelial marker LYVE-1.Quantitation of lymphangiogenesis growth factor VEGF-